Articles tagged with Estrogen
Researchers found that high dietary levels of soy isoflavones do not stimulate cell growth and markers for breast cancer risk in postmenopausal monkeys. The study suggests plant estrogens may contribute to an estrogen profile associated with reduced breast cancer risk.
A recent study found that estrogen-alone hormone therapy may increase the risk of dementia in older postmenopausal women by 49%. This is compared to a placebo group where no such increase was observed. The researchers also found that almost half of the cases in both groups were Alzheimer's disease.
A study found that estrogen alone did not reduce the risk of dementia in older women, doubling the risk compared to placebo. Global cognition also showed no improvement and was even adversely affected in some cases.
A new study shows that estrogen skin patches can counteract high cholesterol associated with hormone therapy for prostate cancer. The patches decreased overall cholesterol levels by 10 percent and increased good cholesterol (HDL), while also improving lipid profiles.
A new study finds that estrogen therapy significantly improves verbal memory performance in men with advanced prostate cancer, while hormone deprivation impairs it. Estrogen also reduces depression and confusion in these patients.
Researchers explore alternative biomarkers for prostate cancer using immune responses to AMACR, while a new RNA interference strategy shows potential in silencing PLK1 genes. The latest AJCC breast cancer staging system revision also influences false-negative rates.
New research indicates that hormone therapy may still offer important health benefits to postmenopausal women. The study's authors argue that the effects of different estrogens and progestins can vary significantly depending on formulation, dosage, and administration method.
Researchers found that estrogen therapy can suppress adrenal androgen production, with marked reductions in DHEA-S, A4, and testosterone levels. The study suggests a potential mechanism for how estrogen affects androgen hormones, and has implications for postmenopausal women.
A randomized trial compared the effects of raloxifene and CEE on bone mineral density in postmenopausal women with prior hysterectomy. The study found that CEE increased bone density by 4.6%, while raloxifene stabilized bone density, and both treatments had varying impacts on cholesterol levels.
Researchers found that hormone-sensitizing compounds can boost estrogen and progestin activity eight- to 10-fold, increasing cancer risk. Exposure to these compounds may be linked to reproductive toxicity, miscarriages, and irregular ovulation.
Researchers found that estrogen-like drugs can reduce body weight gain in postmenopausal women by up to 33% and decrease food intake. The study used an animal model and tested selective estrogen receptor modulators (SERMs) on rats, finding that Eα-selective drugs reduced body weight gain while ERß-selective drugs had no effect.
A year-long study found that postmenopausal women who exercised regularly had significantly lower serum estrogen levels and a reduced risk of breast cancer. The exercise program resulted in a 16.7% reduction in free serum estradiol, a key female sex steroid.
The estrogen-alone study, part of the WHI, found that women taking this form of hormone therapy had an increased risk of stroke, with 44 cases per 10,000 women per year. However, it did not reduce the risk of coronary heart disease. The study involved 10,739 postmenopausal women and was stopped early due to these findings.
A randomized trial of conjugated equine estrogen found no significant effect on coronary heart disease risk, but increased stroke risk and reduced hip fracture risk. The study concluded that estrogen therapy has no overall benefit for chronic disease prevention in postmenopausal women with hysterectomy.
The National Institutes of Health has stopped the estrogen-alone study in healthy postmenopausal women due to an increased risk of stroke, but found no effect on heart disease. The trial also showed a decreased risk of hip fractures and no increase in breast cancer risk.
Women with premature ovarian failure experience higher rates of dry eye due to ocular surface damage, not reduced tear production. Sex hormones play a multifaceted role in maintaining healthy moisture on the eye's surface.
Researchers found that female rats were more sensitive to stress-induced memory errors when estrogen levels were high. Eliminating estrogen from their system reduced this sensitivity, suggesting a key role for estrogen in the vulnerability of women to stress-related mental illnesses.
Researchers at OHSU discovered a novel compound called STX that activates a rapid signaling pathway in nerve cells, providing an alternative to estrogen replacement therapy. The new compound shows promise in alleviating menopause symptoms and may be more effective than existing treatments.
Research suggests that high levels of estrogen can enhance the stress response, leading to greater stress-related cognitive impairments in females. This disparity is consistent with reports of higher prevalence of stress-related disorders in women, particularly during child-bearing years.
Researchers found that the hormone estradiol plays a crucial role in proplatelet formation, enabling the creation of new blood platelets. This discovery may lead to alternative treatments for conditions such as anemia and thrombocytopenia.
Researchers propose combining SERMs with estrogen to prevent breast cancer and improve menopausal symptoms, such as hot flashes and cognitive function. The study found that EM-652 blocks estrogen's negative effects while protecting bone and decreasing serum lipids.
A new study suggests that black cohosh can effectively reduce hot flashes and other menopausal symptoms by binding to serotonin receptors in the brain. The herb is found to have no estrogenic effects, making it a potentially safer alternative to traditional hormone replacement therapies.
Researchers at Rockefeller University have developed a mathematical equation that combines generalized arousal with specific forms of arousal, such as sex and hunger. The study found that genetic changes in mice lacking estrogen receptors can influence overall arousal, providing new insights into the neural mechanisms underlying arousal.
A recent study published in NEJM found that hormone replacement therapy does not effectively slow down the progression of atherosclerosis in postmenopausal women who already have cardiovascular disease. The study suggests that estrogen and progestin may not be effective in treating established coronary artery disease.
Researchers discover that estrogen deficiency triggers immune system activation, leading to increased T cell proliferation and bone loss. This finding could lead to the development of new drugs that prevent postmenopausal bone loss without affecting reproductive organs.
A large study found that estrogen replacement therapy prolongs the QT interval, increasing risk for arrhythmia and heart problems. Women who used hormone therapy had a 50% higher odds of QT prolongation compared to those who never used hormones.
Researchers found a direct link between low dose cadmium exposure and increased risk for breast cancer in female rats. Cadmium mimics estrogen's effects, leading to changes in mammary gland density and uterine weight, similar to early onset of breast cancer.
Research shows estrogens can act as antioxidants, protecting HDL from oxidation and enhancing its ability to shield LDL from damage. High levels of HDL also protect LDL when estrogens are present, with different estrogens displaying varying antioxidant potency.
Women taking long-term combined HRT face a significant increase in breast-cancer risk, doubling the risk for invasive lobular and ductal breast cancer. The study found that both sequential and continuous progestin regimens were associated with similar increases in breast-cancer risk.
Research highlights similar risk factors for women and men, yet varying impacts on heart health. Experts discuss the role of estrogen in blood pressure regulation and cardiovascular disease prevention.
Research found that short-term exposure to ethynylestradiol reduces sperm fertilization capacity in adult male trout. The study showed a 50% decrease in fertility with 10 nanogram per liter of ethynylestradiol, highlighting the potential impact on fish populations.
A study of 16,608 postmenopausal women found that estrogen plus progestin therapy was associated with a 31% higher risk of stroke compared to placebo. The risk for ischemic stroke was particularly elevated, with a 44% increase.
A recent study found that combined hormone therapy increases the risk of dementia in women over 65, doubling the risk compared to placebo groups. The research suggests that hormone replacement therapy may be more harmful than helpful for preventing age-associated memory loss.
A recent study by Wake Forest University Baptist Medical Center found that combination hormone therapy increases the risk of probable dementia in women aged 65 and older, with approximately 23 additional cases per year. The study's results highlight the importance of considering alternative approaches to preventing cognitive decline.
Researchers have identified genetic defects causing excessive estrogen production in three male patients, including a man and his son, leading to severe gynecomastia. The defects involved misplaced promoters associated with housekeeping genes, resulting in continuous aromatase enzyme production and elevated estrogen levels.
MIF is a crucial intermediary in uncontrolled inflammation and impaired wound healing. In estrogen-deficient mice, MIF expression increased, leading to excessive inflammation and delayed healing. Therapeutics that inhibit MIF may accelerate wound healing.
A recent study published in the Journal of the American College of Cardiology found that oral estrogen therapy increased C-reactive protein (CRP) levels, while transdermal estrogen therapy had no effect. The researchers suggest that the route of administration may be a crucial factor in minimizing cardiovascular risks associated with e...
A recent study reveals that estrogen receptors are regularly stripped off DNA to make room for new receptors, enabling cells to continuously sense changes in estrogen levels. This mechanism is essential for the proper functioning of genes and may offer new avenues for therapies in estrogen-related diseases.
Estrogen exposure triggers structural changes in the hippocampus, a primary memory center, increasing connections among neurons. The study provides new insights into the role of estrogen in learning and memory, suggesting potential benefits for postmenopausal women and a possible link to Alzheimer's disease prevention.
Researchers believe initiating hormone replacement therapy in younger women without advanced vessel disease can prevent heart vessel disease. However, delaying HRT may lead to ineffective or potentially harmful effects on older women with more advanced vessel disease.
A study published in the American Association for the Advancement of Science suggests that estrogen levels influence women's ability to suppress pain. The researchers used PET scans to examine the brain's response to pain in individuals with different gender, hormone, and genetic profiles.
Research suggests that high intake of unsaturated fats may be protective against AD, while saturated and trans-unsaturated fats increase risk. Additionally, studies found no association between antioxidant vitamin intake and reduced AD risk.
A recent study found that combination hormone therapy increased the risk of stroke in postmenopausal women, including those with and without high blood pressure. The therapy was found to be ineffective for primary prevention of cardiovascular disease and heart attack.
A recent study by Vanderbilt researchers found that high levels of estrogen can alter the expression of genes related to implantation in mice, leading to a reduced window of receptivity for embryo implantation. This could be contributing to high implantation failure rates in women undergoing IVF.
A study of 95 premenopausal women found a significant link between low estrogen levels and an increased prevalence of coronary artery disease. Women with hypoestrogenemia were more likely to experience adverse coronary arterial dysfunction, suggesting a higher mortality risk.
A recent study published in the Journal of the National Cancer Institute found that combination hormone therapy was associated with a 3-5% increase in breast density, while estrogen alone had no effect. This suggests that increased breast density may be a valid marker for the effect of interventions on breast cancer risk.
Researchers discovered that calcitonin knockout mice have greater bone mass and increased bone formation, suggesting a novel function for the calcitonin gene product. This finding has implications for preventing bone loss associated with estrogen deficiency, potentially leading to new treatments for post-menopausal osteoporosis.
Researchers found that estrogen replacement therapy improved memory performance in rats with ovaries removed, but not when specific cholinergic neurons were destroyed. The study suggests that estrogen may help reduce the risk of Alzheimer's-related dementia in postmenopausal women by affecting these neurons.
A recent clinical trial found that a combination of estrogen and micronized progesterone causes fewer days and less intense bleeding than commonly used hormone replacement therapies. The study suggests that estrogen plus micronized progesterone (MP) may be the form of HRT with the least bleeding and potentially lower health risks.
A study using female rats found that long-term estrogen replacement therapy impaired memory performance, especially when combined with chronic brain inflammation. This effect is analogous to the observed decline in cognitive function in postmenopausal women with Alzheimer's disease who receive continuous estrogen therapy.
Researchers studying walleye fish in Minnesota waterways find high levels of estrogenic chemicals, linked to reproductive changes. Meanwhile, Puerto Rico aquaculture projects test new offshore cages to minimize environmental impact and promote sustainable fisheries.
Researchers have discovered a promising new treatment that preserves bone mass in both female and male mice without affecting reproductive organs. Estren, a class of compounds called ANGELS, appears to trigger bone-building activities without the side effects associated with sex hormone therapy.
A new study found that synthetic hormone estren can build bone in animals without affecting reproductive organs. The researchers tested estren, estrogen, and testosterone in mice with and without sex organs, showing estren's potential to provide a safe form of hormone replacement therapy.
A new study published in the journal Science suggests that estren, a synthetic compound, can build bone and improve bone density and strength without affecting reproductive organs. The findings may indicate a potential alternative to standard hormone replacement therapy for treating osteoporosis in both men and women.
A study of 28 young women found that consuming isoflavone-enriched soy protein supplements for a year did not increase bone mineral density. The researchers assessed the bone mineral content and density of each subject using dual-energy X-ray absorptiometric measurements.
The American College of Physicians' Task Force concludes that combined estrogen and progestin therapy has more likely to cause harm than benefit for most women. The evidence is insufficient to recommend hormone therapy alone or together for preventing chronic conditions in postmenopausal women with hysterectomies.
Researchers found that chemicals in detergents, plastics, and medicines can mimic natural estrogens, disrupting the sexual development of juvenile zebrafish. The study suggests that these compounds can affect not only the reproductive capacity but also sex ratios of fish populations.
A study of 44,241 women found that postmenopausal estrogen-only therapy increases the risk of ovarian cancer by 60%, with a greater risk for those using therapy for 10 or more years. The relative risk was highest for women who used estrogen for 20 or more years.
The Women's Health Initiative has stopped its trial on estrogen-progestin combination Prempro due to significant increased risk of breast cancer and cardiovascular events. Women taking this medication will continue with regular contacts, exams, and mammograms.
A national study on estrogen for postmenopausal women was halted after five years, showing a 26% increased risk of breast cancer and no significant cardiovascular benefits. The study found moderate reductions in fracture and colorectal cancer risk, but the risks outweighed the benefits.